China Lung Cancer Screening Market Size, Share & Trend Analysis Report By Cancer (Non-small Cell, Small Cell), By Diagnosis (Low Dose Spiral CT Scan), By End Use (Hospitals and Clinics), By Region, And Segment Forecasts, 2024 - 2030
This report can be delivered to the clients within 3 Business Days
China Liver Cancer Drug Market Growth & Trends
The China liver cancer drug market size is expected to reach USD 769.09 million by 2030, registering a CAGR of 20.6% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is driven by the increasing incidence of liver cancer. As one of the leading causes of cancer-related deaths in China, the disease presents a substantial public health challenge. According to GLOBOCAN, in 2022, there were approximately 367,657 new cases reported in China, making it the fourth most common cancer in the country, accounting for 7.6% of all new cancer cases. The rising number of cases is attributed to various factors, including high rates of hepatitis B and C infections, alcohol consumption, and other lifestyle-related risk factors. This surge in prevalence necessitates the demand for effective treatment options, thereby accelerating market growth for liver cancer drugs in the region.
Advancements in treatment modalities and improved early diagnostic practices are also critical factors contributing to the growth of the market in China. Progress in targeted therapies, immunotherapies, and combination treatments has enhanced the overall efficacy of liver cancer management, leading to better patient outcomes. Additionally, growing awareness, growing drug approvals, and the adoption of early diagnostic techniques have facilitated timely intervention, which is crucial for improving survival rates. These advancements not only broaden the therapeutic landscape but also create opportunities for pharmaceutical companies to introduce innovative and effective drugs.
Furthermore, the market is expected to benefit from rising healthcare expenditure and increased investment in research and development (R&D). Technological innovations in medical research and government initiatives aimed at improving access to care are playing a vital role in driving market expansion. China's healthcare policies have increasingly focused on enhancing cancer care infrastructure and supporting clinical research, which fosters an environment conducive to market growth. The combination of these factors is expected to sustain a robust demand for liver cancer drugs throughout the forecast period.
Some of the key players in the market are BeiGene, Chi-Med, Innovent Biologics, LianBio, Hengrui Medicine, Jiangsu Chia Tai Tianqing Pharmaceutical, Boehringer Ingelheim, Bristol-Myers Squibb, Roche, Merck & Co., Pfizer, Novartis, AstraZeneca and others. These players are involved in various strategic initiatives such as product launches and approval in order to cater to a global clientele. For instance, in February 2022, HUTCHMED initiated a Phase Ib/II clinical study of HMPL-453, a selective FGFR inhibitor, in combination with chemotherapy or toripalimab, a PD-1 inhibitor, for the treatment of patients with advanced solid tumors in China. The study aims to assess the safety, tolerability, and preliminary efficacy of these combinations in treating patients with advanced cancers, including intrahepatic cholangiocarcinoma (IHCC). This combination approach is intended to enhance therapeutic impact by simultaneously targeting different mechanisms involved in tumor growth and immune evasion. The trial marks a significant step in developing novel combination therapies for difficult-to-treat cancers.
China Liver Cancer Drug Market Report Highlights
China Liver Cancer Drug Market Growth & Trends
The China liver cancer drug market size is expected to reach USD 769.09 million by 2030, registering a CAGR of 20.6% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is driven by the increasing incidence of liver cancer. As one of the leading causes of cancer-related deaths in China, the disease presents a substantial public health challenge. According to GLOBOCAN, in 2022, there were approximately 367,657 new cases reported in China, making it the fourth most common cancer in the country, accounting for 7.6% of all new cancer cases. The rising number of cases is attributed to various factors, including high rates of hepatitis B and C infections, alcohol consumption, and other lifestyle-related risk factors. This surge in prevalence necessitates the demand for effective treatment options, thereby accelerating market growth for liver cancer drugs in the region.
Advancements in treatment modalities and improved early diagnostic practices are also critical factors contributing to the growth of the market in China. Progress in targeted therapies, immunotherapies, and combination treatments has enhanced the overall efficacy of liver cancer management, leading to better patient outcomes. Additionally, growing awareness, growing drug approvals, and the adoption of early diagnostic techniques have facilitated timely intervention, which is crucial for improving survival rates. These advancements not only broaden the therapeutic landscape but also create opportunities for pharmaceutical companies to introduce innovative and effective drugs.
Furthermore, the market is expected to benefit from rising healthcare expenditure and increased investment in research and development (R&D). Technological innovations in medical research and government initiatives aimed at improving access to care are playing a vital role in driving market expansion. China's healthcare policies have increasingly focused on enhancing cancer care infrastructure and supporting clinical research, which fosters an environment conducive to market growth. The combination of these factors is expected to sustain a robust demand for liver cancer drugs throughout the forecast period.
Some of the key players in the market are BeiGene, Chi-Med, Innovent Biologics, LianBio, Hengrui Medicine, Jiangsu Chia Tai Tianqing Pharmaceutical, Boehringer Ingelheim, Bristol-Myers Squibb, Roche, Merck & Co., Pfizer, Novartis, AstraZeneca and others. These players are involved in various strategic initiatives such as product launches and approval in order to cater to a global clientele. For instance, in February 2022, HUTCHMED initiated a Phase Ib/II clinical study of HMPL-453, a selective FGFR inhibitor, in combination with chemotherapy or toripalimab, a PD-1 inhibitor, for the treatment of patients with advanced solid tumors in China. The study aims to assess the safety, tolerability, and preliminary efficacy of these combinations in treating patients with advanced cancers, including intrahepatic cholangiocarcinoma (IHCC). This combination approach is intended to enhance therapeutic impact by simultaneously targeting different mechanisms involved in tumor growth and immune evasion. The trial marks a significant step in developing novel combination therapies for difficult-to-treat cancers.
China Liver Cancer Drug Market Report Highlights
- Based on the drug, the targeted therapy segment accounted for the largest revenue share of 53.10% in 2023. This high share is attributable to advances in molecular biology and genomics which have enabled the development of therapies tailored to specific genetic mutations and biomarkers associated with various cancers, increasing their effectiveness
- Based on type, hepatocellular carcinoma (HCC) accounted for the largest revenue share of 37.41% in 2023. This growth is attributed to the high prevalence and mortality rates associated with HCC are prompting extensive research and development efforts to discover effective treatments
- Based on the distribution channel, hospital pharmacies dominated the market with the largest revenue share of 45.60% in 2023. As the primary point of care for liver cancer patients, hospitals are better equipped with the necessary infrastructure and medical expertise to manage complex therapies and monitor patient responses closely
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. Cancer
1.2.2. Diagnosis
1.2.3. End use
1.2.4. Regional Scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Cancer outlook
2.2.2. Diagnosis outlook
2.2.3. End use outlook
2.3. Regional outlook
2.4. Competitive Insights
CHAPTER 3. CHINA LUNG CANCER SCREENING MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. China Lung Cancer Screening Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitutes
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Environmental landscape
3.3.2.6. Legal landscape
CHAPTER 4. CHINA LUNG CANCER SCREENING MARKET: CANCER ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. China Lung Cancer Screening Market: Cancer Movement Analysis
4.3. China Lung Cancer Screening Market by Cancer Outlook (USD Million)
4.4. Market Size & Forecasts and Trend Analysis, 2018 to 2030 for the following
4.5. Non-small Cell Lung Cancer (NSCLC)
4.5.1. Non-small Cell Lung Cancer (NSCLC) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Small Cell Lung Cancer (SCLC)
4.6.1. Small Cell Lung Cancer (SCLC) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 5. CHINA LUNG CANCER SCREENING MARKET: DIAGNOSIS ESTIMATES & TREND ANALYSIS
5.1. Segment Dashboard
5.2. China Lung Cancer Screening Market: Diagnosis Movement Analysis
5.3. China Lung Cancer Screening Market by Diagnosis Outlook (USD Million)
5.4. Market Size & Forecasts and Trend Analysis, 2018 to 2030 for the following
5.5. Low Dose Spiral CT Scan
5.5.1. Low Dose Spiral CT Scan Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Chest X-ray
5.6.1. Chest X-ray Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 6. CHINA LUNG CANCER SCREENING MARKET: END USE ESTIMATES & TREND ANALYSIS
6.1. Segment Dashboard
6.2. China Lung Cancer Screening Market: End Use Movement Analysis
6.3. China Lung Cancer Screening Market by End Use Outlook (USD Million)
6.4. Market Size & Forecasts and Trend Analysis, 2018 to 2030 for the following
6.5. Hospitals and Clinics
6.5.1. Hospitals and Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Diagnostic Centers
6.6.1. Diagnostic Centers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7. Others
6.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1. Market Participant Categorization
7.2. Key Company Profiles
7.2.1. Biodesix
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. DELFI Diagnostics, Inc.
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. GE HealthCare
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Siemens Healthineers AG
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. Koninklijke Philips N.V.
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. CANON MEDICAL SYSTEMS CORPORATION
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Medtronic
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. Shanghai United Imaging Healthcare Co., LTD
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. Freenome Holdings, Inc.
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. Cancer
1.2.2. Diagnosis
1.2.3. End use
1.2.4. Regional Scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Cancer outlook
2.2.2. Diagnosis outlook
2.2.3. End use outlook
2.3. Regional outlook
2.4. Competitive Insights
CHAPTER 3. CHINA LUNG CANCER SCREENING MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. China Lung Cancer Screening Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitutes
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Environmental landscape
3.3.2.6. Legal landscape
CHAPTER 4. CHINA LUNG CANCER SCREENING MARKET: CANCER ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. China Lung Cancer Screening Market: Cancer Movement Analysis
4.3. China Lung Cancer Screening Market by Cancer Outlook (USD Million)
4.4. Market Size & Forecasts and Trend Analysis, 2018 to 2030 for the following
4.5. Non-small Cell Lung Cancer (NSCLC)
4.5.1. Non-small Cell Lung Cancer (NSCLC) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Small Cell Lung Cancer (SCLC)
4.6.1. Small Cell Lung Cancer (SCLC) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 5. CHINA LUNG CANCER SCREENING MARKET: DIAGNOSIS ESTIMATES & TREND ANALYSIS
5.1. Segment Dashboard
5.2. China Lung Cancer Screening Market: Diagnosis Movement Analysis
5.3. China Lung Cancer Screening Market by Diagnosis Outlook (USD Million)
5.4. Market Size & Forecasts and Trend Analysis, 2018 to 2030 for the following
5.5. Low Dose Spiral CT Scan
5.5.1. Low Dose Spiral CT Scan Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Chest X-ray
5.6.1. Chest X-ray Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 6. CHINA LUNG CANCER SCREENING MARKET: END USE ESTIMATES & TREND ANALYSIS
6.1. Segment Dashboard
6.2. China Lung Cancer Screening Market: End Use Movement Analysis
6.3. China Lung Cancer Screening Market by End Use Outlook (USD Million)
6.4. Market Size & Forecasts and Trend Analysis, 2018 to 2030 for the following
6.5. Hospitals and Clinics
6.5.1. Hospitals and Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Diagnostic Centers
6.6.1. Diagnostic Centers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7. Others
6.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1. Market Participant Categorization
7.2. Key Company Profiles
7.2.1. Biodesix
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. DELFI Diagnostics, Inc.
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. GE HealthCare
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Siemens Healthineers AG
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. Koninklijke Philips N.V.
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. CANON MEDICAL SYSTEMS CORPORATION
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Medtronic
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. Shanghai United Imaging Healthcare Co., LTD
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. Freenome Holdings, Inc.
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives
